InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.011 -0.002 (-15.38%)+
Announcement
Release
6 Jul 2026 8:35AM
Price at Release
$0.013
Full Release
download
Summary
Cynata Therapeutics Limited, a clinical-stage biotechnology company focusing on cell therapeutics, announced major cost-reduction measures and changes in its management structure effective 6 July 2026. The company decided to make all employee positions redundant, including key roles such as the Chief Executive Officer and Managing Director. Board of Directors will manage the company, with some members agreeing to waive their fees. Expenditure reductions included terminating the Phase 2 GvHD trial and other outsourced activities while safeguarding intellectual property. Cynata has secured a $600,000 loan through an R&D Tax Incentive, leveraging the expected rebate for the 2026 fiscal year. These measures are expected to reduce the company's cash burn to approximately $2.3 million for the 2027 financial year, ensuring a cash runway extending beyond the end of that year.
Key Points
  • Redundancy of all employee positions, including CEO and MD
  • Significant reduction in other expenditures while preserving intellectual property
  • Established a $600,000 R&D Tax Incentive loan secured against anticipated R&D TI rebate
  • Proforma cash balance of $1.5m with expected additional R&D TI rebate payment
  • Cash runway extended beyond the end of 2027 financial year
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.